Creatine Monohydrate Group
|
Peak Torque Change (N·m)
|
Phosphocreatine Disodium Salts Plus Blueberry Extract Group
|
Peak Torque Change (N·m)
|
Placebo Group
|
Peak Torque Change (N·m)
|
---|
Subject 1
|
14.45a
|
1
|
21.94a
|
1
|
25.53a
|
2
|
27.50a
|
2
|
16.64a
|
2
|
25.61a
|
3
|
15.01a
|
3
|
−3.31
|
3
|
9.19
|
4
|
16.64a
|
4
|
8.00
|
4
|
−22.38
|
5
|
−6.34
|
5
|
34.63a
|
5
|
4.24
|
6
|
2.06
|
6
|
18.51a
|
6
|
9.27
|
7
|
16.64a
|
7
|
8.80
|
7
|
−3.62
|
8
|
35.38a
|
8
|
28.07a
|
8
|
7.14
|
9
|
0.00
|
9
|
15.27a
|
9
|
8.94
|
10
|
−8.86
|
10
|
26.29a
|
10
|
13.04
|
11
|
20.42a
|
11
|
37.67a
| | |
12
|
11.36
| | | | |
Proportion exceeding the minimal important difference
|
7 of 12 (58%)
| |
8 of 11 (73%) b
| |
2 of 10 (20%)
|
- aIndicates an increase in peak torque across the 28 days of supplementation that exceeded the minimal important difference (pooled pre-supplementation S.D. × 0.5 effect size = 13.29 N·m). b Indicates a significantly (p < 0.05) greater proportion of individual subjects that exceeded the minimal important difference than the placebo group as determined by χ2 analyses